Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Longeveron Posts 32% Revenue Drop in Q2

TheMotleyFool

0 0

Longeveron (NASDAQ:LGVN), a clinical-stage biotechnology firm focused on stem cell therapies for rare and aging-related diseases, released its second quarter earnings on August 13, 2025.

The most notable headline was a deepening net loss for the six months ended June 30, 2025, driven by increased clinical and manufacturing development expenses, while revenue exceeded analyst expectations and the cash runway tightened.

Longeveron reported a basic and diluted net loss per share of $0.33.

Source Fool.com

Like: 0

LGVN

Share